久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • AIM ImmunoTech initiates dosing in intranasal Covid-19 drug study pharmaceutical-technology
    March 10, 2021
    AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.
PharmaSources Customer Service